Cytosorbents Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Cytosorbents Corp. on October 14, 2021. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Monmouth Junction, New Jersey. Its common stock trades on the Nasdaq Capital Market under the symbol CTSO.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a specific corporate event rather than financial performance.
Material Changes
The primary material event reported is the enrollment of the first patient in the Safe and Timely Antithrombotic Removal-Ticagrelor (STAR-T) clinical trial. This double-blind, randomized, controlled trial is designed to support FDA marketing approval for the DrugSorb-ATR Antithrombotic Removal System, specifically for the intraoperative removal of ticagrelor during cardiothoracic surgery.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the clinical trial milestone. The filing does not contain updated financial guidance, specific risk factors, or contingencies beyond the inherent risks associated with clinical trials and regulatory approval processes.
Investor Verification Points
- Verify the full details of the STAR-T clinical trial protocol and endpoints in the referenced press release (Exhibit 99.1).
- Monitor future filings for patient enrollment rates and interim data from the STAR-T trial.
- Confirm the regulatory pathway and timeline for FDA marketing approval of the DrugSorb-ATR system.